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The effect~ of lglucagon and the llluc, tlon-like I'.cptide GLP-1(7=37) were compared in rat liver hepatocytes. Gluea¢8on elevated cAMP, elevated 
intracell ular free calcium {ICon*J0, activated phosphoryht~ and stin)t=lated illu¢oneogenesi~, wherea~ GLP.I(?~37) was without effect on any of 
the~¢ parameters, GLP-1:(7=37] did not block any of the actions of glaeagon, The lllucaBon analog, de( Hi,= t IGItP] glucagon an'tide, was a partial 
agonist in liver, but al~o was an effective antagonist of Illucagon actions in liver but not those of GLP.I (7=37J ht islet B cells, It was cone}uded 
that in the rat, GLP-1(7=37) is a potent Insulin secrelailogue I l l  but is without effect on liver, 
Glueagon.like pcptide.[; Hcpatocyte receptor; Pancreatic B.celI; Insulinotropic; Cyclic AMP 
1. INTRODUCTION 
Glucagon-like peptide-l(7-37) (GLP-I(7-37)) is a 
member of the glucagon family of peptides that 
stimulates ins ulin release [1.4], The peptide is process. 
ed from proglucagon specifically in the intestinal 
neuroendocrine L-cells [51 wherein it is released into the 
circulation in response to oral nutrients [6] and binds to 
and activates cAMP-coupled receptors on the pan- 
creatic B-cells [7-9], Also GLP, l(7-37) partially in- 
hibits glucagon release indirectly from pancreatic 
A-cells and directly promotes somatostatin release 
from pancreatic D.cells [10,11]. These effects of 
GLP-I (7-37) on A-cells are probably indirectly due to 
suppression by insulin and somatostatin through 
paracrine mechanisms; B and D-cells have receptors for 
GLP-I(7--37) whereas A-cells do not [12]. 
There are apparently conflicting data as to the ac- 
tions of GLP-I(7-37) on hepatic metabolism. In fish 
hepatocytes GLPs stimulate gluconeogenesis, but they 
do not employ cAMP as an intracellular messenger 
[13], In rat liver the larger amino terminally-extended 
peptide GLP-I (1-371 does not alter glucagon-mediated 
production of cAMP [14] nor does it stimulate insulin 
release at all [1] or only weakly [15]. Because the short 
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form of GLP-I, GLP-l(7-37), has potent in- 
sulinotropic action [1,2] we sought to evaluate its 
metabolic actions in isolated rat Iiver hepatocytes, We 
also evaluated the capabilities of a synthetic peptide an- 
tagonist of glucagon [16] ~o inhibit glucagon actions in 
rat hepatocytes, This iS an important point because des 
Hist[Glu °] gfucagon-amide is shown not to inhibit 
GLP-I(7-37) actions on pancreatic B-cells. However 
we show that des Hist[Glu 9] glucagon amide does in- 
hibit glucagon effects in B-cells, These observations 
suggest hat distinct receptors exist for GLP-l(7-37) 
and glucagon on B-cells. 
2, MATERIALS AND METHODS 
2,1, Isolation and incubation of hepatoeytes 
He~atocytes were isolated from male Sprague-Dawley rats by col- 
lagenase digestion of the liver as previously described [17], The cells 
(30-40 mg wet.wt/ml) were suspended in Krebs~Henseleit bicar- 
bonate buffer and were incubated in 25 ml Erlenmeyer flasks with 
constant gassing with Oz/CO2 {95:5), 
2.2. Pancreatic tumor B.cell ine (BTC1) 
BTCI cells [181 were passaged and cultured in Dulbecco's Modified 
Eagle's Medium containing 25 tam glucose, 1507o horse serum, 2.507o 
fetal bovine serum, penicillin (100U/ml)  and streptomycin 
(0.1 mg/ml) as described previously [8]. Trypsinized cells were added 
to multiwell plates and allowed to grow to 80-90070 confluence. 
Before beginning the peptide stimulation experiments he cells were 
gently washed three times with the above media modified to contain 
1070 bovine serum albumin rather than serum {control medium). Then 
either control media or medium containing the glucagon antagonist 
des Hisl[Olu 9] glucagon amide was added. After incubation at 37°C 
for 15 rain the agonist peptides, GLP..I(7-37) and/or  glucagon were 
added at one-tenth volume of  10-times the desired final concentration 
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and the cells were Incubatt,'d for an additional I~ rain. AI the ~nd of 
the incubado, the ~:~lls were immediately exlra*.'ted with 
trichioroaeedc acid and froze,+ at =?O*¢ ' for subsequent assay for 
cAMP. 
2.3, Pho,rphoty/~e a mea.~uremenl~ 
Aliquols of =ells (0.$ ml) were removed after i.cuba¢ion with 
various aSents and immediately frozen In liquid N=, Phosphoeyla~e a 
=¢tJvit), wa~, r.;~ur=d 1t; ,.,.|l homosenates as described [I?]. Activity 
is expressed as unltsof [U -!* C]fllucose I.phosphale incorporated into 
ltlycolten per 8 of wet.wt Of tissue per rain. 
2.4, c'.~1 AlP d¢tert#llltlllOtl.~ 
cAMP was measured by a radioimmtmoassay in diluted 
|richloroac©dc acid extracts of hepatocyte suspensions b)" the method 
of Steiner el al, [19} as modified by Harper and Brooker [20l, This 
method has been successfully adapted to measure cAMP in rat liver 
hepatocytes [21], Cyclic AMP levels in extracts of BTCI cells were 
measured usin8 a radioinlm.noassay s described previously [?]. 
2.5, GhtcotleOge/~e.~t3 detertni/tal/Ota 
The rate of llluconcogenesis was determined by measuriaB the con. 
version of S mM [*'*C]lactate to [t'*Clglucos¢ during a 20 rain incuba. 
tion [22], The data (see section 3)are expressed as e/o of control rate 
I.= of ( C]glucos¢ formation and are means .*- $EM from 3 separate ex- 
periments. 
2,6, Free intrace/lu/ar calcium nteaxuretnents 
The changes In [Ca" li were me,tsured as previously outlined [23} 
utilizing furs 2 as the Ca z• indicator. 
3. RESULTS AND DISCUSSION 
Glucagon-like peptide-l(7-37) does not increase 
cAMP levels when added at concentrations ranging bet- 
ween l0 "t° to 10-~M (Fig. 1). Glucagon, however, 
elevates cAMP (Fig. 1). The inclusion of 10"aM 
GLP-l(7-37) as a potential antagonist of the actions of 
glucagon had no effect on the action of glucagon to 
elevate cAMP (Fig. l). These data show that 
GLP-I(7-37) is neither an agonist nor an antagonist of 
glucagon actions in hepatocytes when cAMP levels are 
measured. 
To further determine that GLP-1(7-37) was without 
effect in hepatocytes, the effectiveness of GLP-l(7-37) 
to activate phosphorylase was measured. Consistent 
with the data in Fig. 1, GLP-I(7-37) did not activate 
phosphorylas¢ when added at concentrations ranging 
between 10 -tt to 10 -~ M (data not shown). Glucagon 
did increase phosphorylase a, with a maximum twofold 
increase observed with approximately l0 -9 M. 
However the inclusion of 10 -a M GLP-I(7-37) with 
glucagon (10 -tt to 10 -~ M) had no effect on the ability 
of glucagon to elevate phosphorylase a (data not 
shown). 
Glucagon has been shown to stimulate calcium influx 
[Ca2*]i [24,25], although the precise mechanism by 
which it does this is not known. We find that 
GLP-l(7-37) at either 10-TM or 10-aM does not 
elevate [Ca2+]i  in conditions in which glucagon 10 -'~ M 
elevated [Ca2+]i to a level similar to that obtained with 
10 -9 M vasopressin (Fig. 2). 
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Fig, I. Dose-response of GLP.I(7-37), Ulucagon, and glueagon in 
tile presence of GLP.I(7-3'7) on cAMP levels, Flepatocytes were 
incubated for three min with tile appropriate concentrations of 
GLP-1(7-3"/) and glucagon, Aliquots of O,S ml were removed after 
3 min into 0.5 mlo f  ice-cold 10~'o TCA, After removal of protein by 
centrifugatlon, the amount of cAMP was measured by 
radioimmunoassay (see section 2 for details), The data shown 
(mean ± SEM) are front a representative experiment performed in 
triplicate and assayed in duplicate. 
An important metabolic effect of glucagon in the 
liver is to stimulate gluconeogenesis [26]. GLP-l(7-37) 
l0 -s M was unable to stimulate gluconeog'enesis (106 ± 
11070 of control). Glucagon (10 -s  M) produced a 
substantial increase in gluconeogenesis (262 ± 46°7o f 
control). The ability of l0 -a M glucagon to stimulate 
gluconeogenesis was not modified by the inclusion of 
l0 -v M GLP-[(7-37) in the incubation (246 ± 3507o f 
control). To determine whether the lack of 
GLP-l(7-37) effects on the hepatocytes was not due to 
loss of activity during handling of the sample, an ali- 
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Fig. 2. Effect of GLP-I (7-37), glucagon, and vasopressin on [Ca 2.]i 
in hepatocyte suspensions. Peptides were added to furs 2-loaded 
bepatozytes 15 s after data collections were started. Calibration was 
performed as detailed previously [23]. 
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ed in the above described expetimenls was a~sayed in 
the ra~ perfased pancreas as described previously [1,4]. 
The stimulation of insulin secretion m 1O "u M concen- 
tration was similar to the effect obtained from the 
freshly prepared GLP-I( ' / -37) stock solution (G, Hen- 
drtcks and G. Weir, persona[ communication), 
To confirm that the actions of glucagon could be 
blocked by an antagonist at the receptor level, the 
glucagon analog des His ~ [Glu '~] glucagon amid¢, which 
has been reported to be a glucagon antagonist [16]:, was 
milized. We found that ! ,.M des His~[Giu ~] glucagon 
amide is a partial agontst because it elevated cAMP 
levels Prom 473 ¢ 29 to 1091 = 131 fmol/mg. However, 
it was also a very good antagonist of the effects of 
glucagon on cAMP levels, especially when the hormone 
was present at 10 =9 M and 10"~M (FIB. 3), When 
lower concentrations of  des His![Glu +~] glucagon amidc 
were utilized (e.g., 100 nM), there was very little inhibi- 
tion of glucagon effects (data not shown), The 
glucagon antagonist des His'[Glug] glucagon amide 
(i +#M) also activated phosphorylas¢ a by itself (approx. 
50% of that observed with 10 -~ M glucagon) and an- 
tagonized the effects of glucagon in the concentrations 
10 -~° M to 10 =s M (data not shown), At a concentra- 
tioa of  10 -7 M glucagon, there was no inhibition of 
phosphoryiase a activity by the des His ~ [Glu 9] glucagon 
amide (data not shown), 
In contrast to the absence of any effects of 
GLP.I(7-37) on the rat liver hepatocytes, it has been 
shown that the peptide potently stimulates the pan- 
creatic B-cells to release insulin, increase cAMP forma- 
tion and elevate proinsulin gene expression [1,4,7-9]. 
Importantly, the glucagon antagonist, des Hist[Glu 9] 
$1uca$on amid+ (I.0 =' M) does not  antajonixe the 
GLP-IC/-3"/) (I0 ~+ M) stimulated formmion of cAMP 
in pgncreatic B.cells (Fill. 4), The effe¢t of glucalon 
(10 =" M) on cAMP formation, in B.celis, however, is 
abrogated by the glucagon antagonist (10+~M), 
although the antagonist has agonist activity at this con- 
centraUon (Fig. 4), Inasmuch as gtacagon is approx- 
imately 100-fold less potent than GLP- IO-37) in 
releasing insulin in the perfused rat pancreas [4] and in 
stimulating formation of cAMP in B-cells [451, it was 
necessary to, use [O="M glucagon and 10" M des 
His l[Glu ~] glucagon amide to achieve fl~e am agonistic 
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Fig. 3 Dose-response of glucagon to elevate cAMP in the presence 
and absence of des His~[Glu 9] glucagon amide. Hepatocytes were 
incubated for 3 rain with the appropriate concentrations of glucagon 
in the presence and absence of  1 uM des His'[Glu 9] glucagon amide 
(added simultaneously), Al iquots were removed for the measurement 
of cAMP levels as detailed in legend to Fig. 1. Data shown are the 
means ± SEM from 3 separate incubations, assayed in duplicate. 
Significant differences are indicated by * P < 0.05 and ** P < 0.01 
(analysis by Student's t-test for paired observations), 
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Fig, 4. Effects of GLP-I(7-37), glucagon and tile glucagon 
antagonist des His'[Glu 9] glucagon amide on the formation of cAMP 
in pancreatic B-cells. Mouse BTCl cells were treated with either 
control media or media plus antagonist, des His'lGlu 9] glucagon 
amide, for 15 rain and then agonist, GLP. I (7-37) or glucagon were 
added. After 15 rain, cells were extracted and assayed for cAMP. A 
typical dose-response for GLP. I(7-37) is sllown on the left (black 
bars). The glucagon antagonist (10:6 M) prevents stimulation of 
cAMP by glucagon (10 -8 M) but at IO-TM does not inhibit 
stimulation of cAMP by GLP.I(7-3"/) (10 -9 M) (middle0 shaded 
bars). GLP.I(7-37) l0 -s M is additive with glucagon (10-6 M) in 
stimulating cAMP formation (right, cross-hatched bars). Note that 
the lower level of cAMP at 10-~M compared to 10-~M 
GLP-I(7-37) is a result of some homologous desensitization f the 
receptor [9]. Tile experiment was done twice, each time using 
quadruplicate wells of cells and assay of cAMP in cell extracts 
prepared from each of the four wells was done in quadruplicate. The 
values shown are means ± SEM of the average cAMP levels for the 
4 wells of cells, 
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(10 =n M) were partially addit ive in the stimulation of 
cAMP formation in B.cells (Fig. 4). GLP- l (7 -37)  at 
10 =a M has been shown to maximally stimulate cAMP 
formation in B.cells [7,9]; higher concentratiol~ o f  the 
peptide result in less cAMP generation due to a 
homologous desensitization of the B-cell receptor  [9]. 
The data presented in this study clearly show that 
GLP- I (7 -37)  does not stimulate, in the rat, hepatic 
glycogenolysis (measured by phosphorylase activation) 
or glueoneogenesis (measured by the conversion of 
[=4C]lactate to [t~C]$1ucose), GLP- i (7 -37)  also does 
not increase the intracellular second messengers cAMP 
and Ca =" in rat liver, These data are not consistent with 
those ['ound in fish where GLP- I  functions as a 
metabolic hormone [27] and activates hepatic 
gluconeogenesis [13]. These discrepancies in observa. 
tions may be more apparent han real, There exists a 
large family of  peptides related in their  structure ~o 
glucagon including among others, vasoactive intestinal 
peptide, gastric inhibitory peptid¢, secretin, growth 
hormone releasing hormone, the salivary gland pep- 
tides (helospectins, helodermins), as yet uncharacteriz- 
¢d brain peptides and the glucagon-like peptides l and 
2, The fish glucagon-related peptides co.encoded with 
glucagons in the two nonallelic genes have structures 
that differ considerably from the mammal ian GLP- ls ,  
Inasmuch as there must: exist corresponding receptors 
for all of  these peptides, it is reasonable to propose that 
certain of the peptides will cross,react with the recep- 
tors of other peptides, especially when crossing species, 
e.g. rat and fish and liver hepatocytes. Alternatively 
since there is a conservation of amino acid sequence 
between fish GLP- Is  and mammal ian GLP- I (7 -37)  
[28] the discrepancies between our results and those ob- 
tained with fish hepatocytes may also be explained by 
differences in glucose metabol ism between fish and 
mammals.  
In conclusion it appears from our findings that the 
pancreatic B-cell is a major and  important arget for 
GLP- l (7 -37)  and the role of the peptide is to stimulate 
the secretion of insulin and to thereby suppress the 
secretion of glucagon. Therefore, GLP- l (7 -37)  is an 
anabolic hormone and as such it is physiologically rele- 
vant that it not have receptors on hepatocytes that 
would be glucagon-like in their catabolic actions. 
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